Tag Archives: AZD-0914

AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug

Posted on by — No Comments ↓

At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. difficile. In addition, researchers mention a peculiar MoA for this gyrase/topoisomerase Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug→

MRSA Fluoroquinolones – An Interesting Bunch Playing a High-Stakes Game

Posted on by — No Comments ↓

Fluoroquinolones (FQ) of the ofloxacin/ciprofloxacin generation were mainly active against Gram-negative bacteria, distinguishing themselves as cidal IV/PO drugs with high potency against most lactose- and non-lactose fermenters.  They were excellent against problem pathogens like P. aeruginosa, had excellent efficacy against Salmonellae, the Gonococcus and other Neisseriae, and you could count on them for Continue reading MRSA Fluoroquinolones – An Interesting Bunch Playing a High-Stakes Game→

QIDP Drugs – 4th Edition

Posted on by — No Comments ↓

>>> For the latest QIDP list, please click HERE  <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It also indicates whether a drug has been the topic of a Continue reading QIDP Drugs – 4th Edition→